Drug Profile
Research programme: small molecule isoxazoles - LoneStar Heart/University of Texas Southwestern Medical Center/University of Texas at San Antonio
Latest Information Update: 13 Sep 2023
Price :
$50
*
At a glance
- Originator LoneStar Heart; University of Texas Health Science Center at San Antonio; University of Texas Southwestern Medical Center
- Class Isoxazoles; Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Diabetes mellitus; Heart failure
Most Recent Events
- 13 Sep 2023 Discontinued - Preclinical for Diabetes mellitus in USA (unspecified route) ((https://pitchbook.com/profiles/company/42705-73#overview))
- 13 Sep 2023 Discontinued - Preclinical for Heart failure in USA (unspecified route) (https://pitchbook.com/profiles/company/42705-73#overview)
- 28 Sep 2020 No recent reports of development identified for preclinical development in Diabetes-mellitus in USA